LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel ; Online: Monoclonal Antibodies and Airway Diseases

    Annina Lyly / Anu Laulajainen-Hongisto / Philippe Gevaert / Paula Kauppi / Sanna Toppila-Salmi

    International Journal of Molecular Sciences, Vol 21, Iss 9477, p

    2020  Band 9477

    Abstract: Monoclonal antibodies, biologics, are a relatively new treatment option for severe chronic airway diseases, asthma, allergic rhinitis, and chronic rhinosinusitis (CRS). In this review, we focus on the physiological and pathomechanisms of monoclonal ... ...

    Abstract Monoclonal antibodies, biologics, are a relatively new treatment option for severe chronic airway diseases, asthma, allergic rhinitis, and chronic rhinosinusitis (CRS). In this review, we focus on the physiological and pathomechanisms of monoclonal antibodies, and we present recent study results regarding their use as a therapeutic option against severe airway diseases. Airway mucosa acts as a relative barrier, modulating antigenic stimulation and responding to environmental pathogen exposure with a specific, self-limited response. In severe asthma and/or CRS, genome–environmental interactions lead to dysbiosis, aggravated inflammation, and disease. In healthy conditions, single or combined type 1, 2, and 3 immunological response pathways are invoked, generating cytokine, chemokine, innate cellular and T helper (Th) responses to eliminate viruses, helminths, and extracellular bacteria/fungi, correspondingly. Although the pathomechanisms are not fully known, the majority of severe airway diseases are related to type 2 high inflammation. Type 2 cytokines interleukins (IL) 4, 5, and 13, are orchestrated by innate lymphoid cell (ILC) and Th subsets leading to eosinophilia, immunoglobulin E (IgE) responses, and permanently impaired airway damage. Monoclonal antibodies can bind or block key parts of these inflammatory pathways, resulting in less inflammation and improved disease control.
    Schlagwörter airways ; asthma ; chronic rhinosinusitis ; biologicals ; monoclonal antibody ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Thema/Rubrik (Code) 610
    Sprache Englisch
    Erscheinungsdatum 2020-12-01T00:00:00Z
    Verlag MDPI AG
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  2. Artikel: Lung function and side effects of Aspirin desensitization: a real world study.

    Heikki, Turpeinen / Anu, Laulajainen-Hongisto / Annina, Lyly / Jura, Numminen / Elina, Penttilä / Sahlman, Johanna / Sanna, Toppila-Salmi / Paula, Kauppi

    European clinical respiratory journal

    2021  Band 8, Heft 1, Seite(n) 1869408

    Abstract: ... ...

    Abstract Introduction
    Sprache Englisch
    Erscheinungsdatum 2021-01-11
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2834928-3
    ISSN 2001-8525 ; 1399-3003 ; 2001-8525 ; 0903-1936
    ISSN (online) 2001-8525 ; 1399-3003
    ISSN 2001-8525 ; 0903-1936
    DOI 10.1080/20018525.2020.1869408
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang